Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by farmerjaneon Dec 03, 2019 3:33pm
98 Views
Post# 30418465

RE:RE:Biogen

RE:RE:BiogenMore than 3 years ago they were presenting there theory of toxic oligomers to pharma companies "supposedly", while Biogen initiated two large phase 3 trials in 2015 and was the front runner with it's Aducanumab. A lot of time before march of this year for pharma to strike a deal  if Promis is the real deal. Didn't happen!! Been talking about potential partnering for better than 3 years? No deals? PD more than a year and half ago "We are actively pursuing discussions with large pharma regarding partnering of these two new toxic oligomer programs. Clearly missed the IND filing deadline posted a couple of years ago. 
If they had the real deal they would have a deal by now, instead of feeding the nonsense these things take time.
Financing are beginnng to look like a pyramid scheme with the same playes at the table.  
Bullboard Posts